Ed­i­tas and Blue­Rock join forces — and plat­form tech­nolo­gies — on a new wave of en­gi­neered cell ther­a­pies

Two promi­nent Boston-based biotechs are ty­ing their plat­form tech­nolo­gies to­geth­er to see how they can give each oth­er a boost to their re­spec­tive pipelines.

In a deal an­nounce­ment shorn of any men­tion of cash, the gene edit­ing pi­o­neers at Ed­i­tas have agreed to share their CRISPR plat­form with Blue­Rock, a well fund­ed stem cell play­er — which launched with a $225 mil­lion round — look­ing to play a lead­ing role in the sec­ond wave of drug de­vel­op­ment go­ing on now in the re­gen­er­a­tive med­i­cine field.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER